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Objectives: To determine the antibiotic resistance and fingerprint profiles of methicillin-resistant coagulase-
negative staphylococci (MRCoNS) from animal infections among different practices and examine the history
of antibiotic treatment.
Methods: Isolates were identified by mass spectrometry and tested for antimicrobial resistance by broth dilu-
tion, microarrays and sequence analysis of the topoisomerases. Diversity was assessed by PFGE, icaA PCR and
staphylococcal cassette chromosome mec (SCCmec), arginine catabolic mobile element (ACME) and multilocus
sequence typing. Clinical records were examined retrospectively.
Results: MRCoNS were identified as Staphylococcus epidermidis (n¼20), Staphylococcus haemolyticus (n¼17),
Staphylococcus hominis (n¼3), Staphylococcus capitis (n¼1), Staphylococcus cohnii (n¼1) and Staphylococcus
warneri (n¼1). PFGE identified one clonal lineage in S. hominis isolates and several in S. haemolyticus and S.
epidermidis. Fourteen sequence types were identified in S. epidermidis, with sequence type 2 (ST2) and ST5
being predominant. Ten isolates contained SCCmec IV, seven contained SCCmec V and the others were non-
typeable. ACMEs were detected in 11 S. epidermidis isolates. One S. hominis and 10 S. epidermidis isolates
were icaA positive. In addition to mecA-mediated b-lactam resistance, the most frequent resistance was to
gentamicin/kanamycin [aac(6′)-Ie–aph(2′)-Ia, aph(3′)-III] (n¼34), macrolides/lincosamides [erm(C), erm(A),
msr, lnu(A)] (n¼31), tetracycline [tet(K)] (n¼22), streptomycin [str, ant(6)-Ia] (n¼20), trimethoprim [dfr(A),
dfr(G)] (n¼17), sulfamethoxazole (n¼34) and fluoroquinolones [amino acid substitutions in GyrA and GrlA]
(n¼30). Clinical data suggest selection through multiple antibiotic courses and emphasize the importance
of accurate diagnosis and antibiograms.
Conclusions: MRCoNS from animal infection sites are genetically heterogeneous multidrug-resistant strains that
represent a new challenge in the prevention and therapy of infections in veterinary clinics.
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Introduction
Coagulase-negative staphylococci (CoNS) are frequently found
on the skin and mucous membranes of humans and animals.1
They are opportunistic pathogens and are one of the most fre-
quent causes of nosocomial infections in humans, which are
mainly associated with immune-compromised patients or with
the implantation of medical devices.2–6 Staphylococcus epider-
midis is the most frequent CoNS causing infection in humans,
and 70% of the S. epidermidis strains circulating in the human
hospital environment have been estimated to be resistant to
methicillin and most of them display additional resistance to
other classes of antibiotics.7 The acquisition of methicillin
resistance in staphylococci results from the recombinase-
mediated insertion of the staphylococcal chromosomal cassette
mec (SCCmec), the mobile genetic element that carries mecA.8,9
The mecA gene encodes the binding protein PBP2a, which med-
iates resistance to all b-lactam antibiotics in staphylococci.10
Other methicillin-resistant CoNS (MRCoNS), such as Staphylococcus
haemolyticus, Staphylococcus hominis, Staphylococcus capitis,
Staphylococcus sciuri, Staphylococcus warneri and Staphylo-
coccus saprophyticus, have also been described as causes of
clinical human infections.11–13 In some S. epidermidis strains,
the SCCmec elements have been found to be associated with
the arginine catabolic mobile element (ACME), enhancing fitness
and the ability to colonize the host.14–16 These characteristics
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associated with the ability to produce a biofilm are important
factors for establishing CoNS, especially S. epidermidis, as noso-
comial pathogens.2,17,18
In veterinary medicine, many different classes of antibiotics
are used for the treatment of infections. The use of such antibio-
tics has likely selected for an antibiotic-resistant commensal
flora, as healthy pets and horses have been found to be colo-
nized with MRCoNS.4,19–22 However, very few reports describe
cases of infections caused by MRCoNS in these animals,23–25
although several studies have reported infections with methicillin-
susceptible CoNS.26–30 In the past 4 years, MRCoNS have been iso-
lated from the infection sites of pets and horses in Switzerland.
The genetic backgrounds of these multidrug-resistant clinical
isolates and their clonal relationships remained to be elucidated.
This study provides the first substantial molecular characterization
of MRCoNS associated with infections in pets and horses and
determines whether specific clones are becoming established in
veterinary settings. The history of antibiotic usage as well as the
treatment and outcome of the infections are also provided to
support the hypothesis that several courses of different antibiotics
may have selected for multidrug-resistant CoNS. This study may
also serve as a basis for future epidemiological and prevalence
studies of MRCoNS circulating in veterinary clinics and other
animal environments.
Materials and methods
Sample collection, isolation and identification
Samples were taken by veterinarians from different infection sites of pets
and horses that did not respond to antibiotic therapy and sent for iden-
tification of the causative agents and antibiograms to the Centre for Zoo-
noses, Bacterial Animal Diseases and Antibiotic Resistance (ZOBA) of the
Institute of Veterinary Bacteriology, University of Bern, Bern, Switzerland,
the IDEXX Diavet Laboratory, Ba¨ch, Switzerland, or the Laboratory Laupe-
neck AG, Bern, Switzerland. Isolates of MRCoNS that appeared to be the
primary pathogens [either as single pathogenic agent (n¼40) or together
with a second pathogen (n¼3)] were kept at 2808C and made available
for this study. A total of 43 isolates were collected between 2005 and
2011 (see Tables 1 and 2). They were routinely cultivated on Tryptone
soy agar containing 5% sheep blood (TSA-SB) (Oxoid Ltd, Basingstoke,
England) and incubated aerobically for 18 h at 378C. Species identifica-
tion was determined phenotypically using Vitek2 (bioMe´rieux, Marcy
l’E´toile, France) and matrix-assisted laser desorption/ionization time of
flight mass spectrometry (MALDITOF-MS) (Microflex LT, Bruker Daltonik,
Bremen, Germany).
Genotyping
PFGE was performed on DNA digested with SmaI as described previous-
ly.23 PFGE was run on a CHEF DRIII apparatus (Bio-Rad, Hercules, CA, USA)
for 21 h at 6 V/cm and with pulse time ramping from 5 to 40 s at 128C.
The PFGE profiles were defined on the basis of DNA banding patterns in
compliance with the criteria of Tenover et al.31 for bacterial strain
typing using the BioNumerics software (version 6.6, Applied Maths,
Saint-Martens-Latem, Belgium).
SCCmec typing was determined by multiplex PCR.32 SCCmec types
were defined by the combination of the type of ccr complex and the
class of mec complex: SCCmec type I (mec complex B, ccrAB1), SCCmec
type II (mec complex A, ccrAB2), SCCmec type III (mec complex A,
ccrAB3), SCCmec type IV (mec complex B, ccrAB2) and SCCmec type V
(mec complex C, ccrC). SCCmec was classified as non-typeable when
the ccr complex, the mec complex or both could not be amplified by PCR.
The presence and type of ACMEs were determined by PCR using the
primer pairs AIPS.27-AIPS.28 (arcA) and AIPS.45-AIPS.46 (opp3A) as
described previously.33 ACMEs were classified into three allotypes: ACME
type I containing both the arc and opp-3 gene clusters, ACME type II con-
taining arc but not opp-3 and ACME type 3 containing opp-3 but not arc.14
The presence of the biofilm-formation operon ica was determined by
amplification of the icaA gene by PCR.34 S. epidermidis samples were
characterized by multilocus sequence typing (MLST).35 PCR amplifications
were routinely performed using FIREPol DNA polymerase (Solis BioDyne,
Tartu, Estonia), except for SCCmec typing, which was performed with
the Expand Long Template PCR System (Roche Applied Science, Rotkreuz,
Switzerland).
Determination of the antibiotic resistance profile
MICs were determined in Mueller–Hinton broth by use of custom Sensi-
titre NLEUST plates (Trek Diagnostics Systems, East Grinstead, UK; MCS
diagnostics BV, JL Swalmen, the Netherlands). The MIC breakpoints deter-
mining resistance were those recommended for staphylococci by EUCAST
(www.eucast.org), except for streptomycin and kanamycin, for which
breakpoints came from the French Society for Microbiology (www.
sfm-microbiologie.org), and sulfamethoxazole, for which they came
from the CLSI.36 No breakpoint was available for tiamulin and resistance
was attributed after the detection of a tiamulin resistance gene. The
antimicrobial agents tested and breakpoints used consisted of
chloramphenicol (.8 mg/L), ciprofloxacin (.1 mg/L), clindamycin
(.0.5 mg/L), erythromycin (.2 mg/L), fusidic acid (.1 mg/L), gentamicin
(.1 mg/L), kanamycin (.16 mg/L), linezolid (.4 mg/L), mupirocin
(.256 mg/L), oxacillin (.0.25 mg/L), penicillin (.0.125 mg/L), quinupris-
tin/dalfopristin (.4 mg/L), rifampicin (.0.5 mg/L), streptomycin (.16 mg/
L), tetracycline (.2 mg/L), tiamulin (resistance breakpoint not available),
trimethoprim (.4 mg/L), sulfamethoxazole (.256 mg/L) and vancomycin
(.2 mg/L). Antibiotic resistance genes were detected using a custom-
made microarray (AMR+ ve-2 array tubes, Alere Technologies GmbH,
Jena, Germany).37 The microarray results were analysed using the Icono-
Clust program (Alere) and the signals obtained were interpreted visually.
The acquired trimethoprim resistance dihydrofolate reductase gene
dfr(A) in S. epidermidis was distinguished from the chromosomal dfr(A)
(¼ folA) by PCR using one primer specific to dfr(A) and one primer specific
to IS431, which is only situated downstream of the acquirable dfr(A)
gene and not downstream of the chromosomal dfr(A) of S. epidermidis
(Table S1, available as Supplementary data at JAC Online).
Mutations in the fluoroquinolone resistance coding region of the topo-
isomerase II (GyrA and GyrB) and IV (GrlA and GrlB) genes were deter-
mined by sequence analysis of PCR products obtained using the
primers listed in Table S1 (available as Supplementary data at JAC
Online). Mutations were detected by comparison of the amino acid
sequences of GyrA, GyrB, GrlA and GrlB of fluoroquinolone-susceptible
S. epidermidis ATCC12228 (GenBank accession number AE015929),
S. haemolyticus JCSC1435 (GenBank accession number NC_007168)
and S. hominis SN-013-2010-6-23-5 (GenBank accession numbers
HE820118 and HE856265).
Clinical data and statistical analysis
Clinical records of animals that developed an infection containing
MRCoNS were examined retrospectively when available. The following
data were recorded: underlying diseases, history of antibiotic treatments,
specific antibiotic treatment of the infection and outcome (see Table 3).
PASS 2008 software (NCCS, Kaysville, UT, USA) was used to conduct
a Fisher’s exact test (two-tailed) with the level of significance set at a
P value ,0.05.
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Table 1. Origin and resistance profile of methicillin-resistant S. epidermidis isolated from infection sites of animals
Isolate
(n¼20)
Year of
isolation Animal Infection
Sequence
type
Antibiotic resistance properties and resistance breakpoints (mg/L)
OXA PEN GEN/KAN KAN STR STH ERY CLI TMP TET CHL TIA MUP FUS SMX
CIP
.0.25 .0.125 .1/.16 .16 .16 ND .2 .0.5 .4 .2 .8 NA .256 .1 .256
.1
GyrA GrlA
CSNO38 2005 horse dermis ST446 mecA blaZ aac(6′)-Ie – aph(2′)-Ia aph(3′)-III ant(6)-Ia,
str
sat4 erm(C) erm(C) dfr(A) tet(K) R
KM794-06 2006 horse abscess ST89 mecA blaZ aac(6′)-Ie – aph(2′)-Ia tet(K)
KM1527-07 2007 cat joint ST22 mecA blaZ aac(6′)-Ie – aph(2′)-Ia dfr(A) S84Y S80F
KM827-09 2009 cat respiratory
tract
ST59 mecA blaZ aac(6′)-Ie – aph(2′)-Ia aph(3′)-III str sat4 tet(K) R
KM505-09 2009 cat urinary
tract
ST22 mecA blaZ aac(6′)-Ie – aph(2′)-Ia erm(C) erm(C) dfr(A) tet(K) catpC223 R S84Y D84Y
KM1077-09 2009 dog abscess ST2 mecA blaZ dfr(A) mupR R R S84Y S80Y/D84Y
KM92-09 2009 dog abscess ST2 mecA blaZ aac(6′)-Ie – aph(2′)-Ia dfr(A) R
KM825-09 2009 horse abscess ST451 mecA blaZ aac(6′)-Ie – aph(2′)-Ia R S84F D84Y
IMD1265-11 2011 horse dermis ST69 mecA aac(6′)-Ie – aph(2′)-Ia erm(C) erm(C) tet(K) mupR
IMD1274-11 2011 cat dermis ST5 mecA blaZ erm(C) erm(C) tet(K) S84F S80Y
IMD1763-11 2011 cat urinary
tract
ST81 mecA blaZ aac(6′)-Ie – aph(2′)-Ia tet(K)
IMD1270-11 2011 cat abscess ST2 mecA blaZ aac(6′)-Ie – aph(2′)-Ia aph(3′)-III ant(6)-Ia sat4 erm(C) erm(C) dfr(A) tet(K) vga(A) R S84F S80F/D84Y
IMD1269-11 2011 cat urinary
tract
ST445 mecA blaZ aac(6′)-Ie – aph(2′)-Ia erm(C),
msr,
mph(C)
erm(C) R R S84F S80Y
IMD1528-11 2011 cat dermis ST448 mecA blaZ aph(3′)-III erm(C),
mph(C)
erm(C) dfr(G)
IMD1776-11 2011 cat eye ST286 mecA blaZ R R erm(C) erm(C) dfr(G)
IMD1766-11 2011 dog ear ST5 mecA blaZ erm(C) erm(C) R S84F S80F/D84Y
IMD1778-11 2011 dog respiratory
tract
ST5 mecA blaZ R S84F S80Y
KM1385-1972 2011 dog joint ST450 mecA blaZ R R
IMD1764-11 2011 dog respiratory
tract
ST449 mecA blaZ erm(C),
mph(C)
erm(C) R
IMD1765-11 2011 dog respiratory
tract
ST2 mecA blaZ aac(6′)-Ie – aph(2′)-Ia str sat4 erm(C) erm(C) dfr(A) catpC221 R R S84F S80F/D84Y
CHL, chloramphenicol; CIP, ciprofloxacin; CLI, clindamycin; ERY, erythromycin; FUS, fusidic acid; GEN, gentamicin; KAN, kanamycin; MUP, mupirocin; OXA, oxacillin; PEN, penicillin; STR,
streptomycin; STH, streptothricin; TET, tetracycline; TIA, tiamulin; TMP, trimethoprim, SMX, sulfamethoxazole; ND, not defined, susceptibility to streptothricin was not measured, only
the gene was detected; NA, no resistance breakpoint available for tiamulin [resistance to tiamulin was attributed in the presence of the vga(A) gene (MIC .4 mg/L)]; R, resistant
phenotype, no resistance genes were determined; blank spaces indicate either no resistance or no mutations.
The MIC breakpoints (in mg/L) that determine resistance were those recommended by EUCAST for staphylococci (www.eucast.org). Resistance breakpoints for streptomycin and kanamy-
cin were those recommended by the French Society for Microbiology (www.sfm-microbiologie.org) and the resistance breakpoint for sulfamethoxazole was that recommended by the
CLSI.36
Antibiotic resistance genes and their functions are indicated as follows:mecA, methicillin-resistance gene encoding PBP2a for resistance to all b-lactam antibiotics; blaZ, b-lactamase gene;
aac(6′)-Ie–aph(2′)-Ia, aminoglycoside acetyltransferase and phosphotransferase tandem genes; aph(3′)-III, kanamycin phosphotransferase; ant(6)-Ia, streptomycin adenylnucleotidyl-
transferase gene; str, streptomycin adenyltransferase gene; sat4, strepthothricin acetyltransferase gene; erm(C), macrolide, lincosamide and streptogramin B 23S rRNA methylase
gene; msr, macrolide and streptogramin ATP binding transporter gene; mph(C), macrolide phosphotransferase gene; mupR, isoleucyl-tRNA synthetase gene; dfr(A), dfr(G), trimethoprim
resistance dihydrofolate reductase gene; tet(K), tetracycline efflux resistance gene; catpC221, catpC223, chloramphenicol acetyltransferase gene; vga(A), pleuromutilin and streptogramin
A ATP binding transporter gene.
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Table 2. Origin and resistance profile of methicillin-resistant S. haemolyticus, S. hominis, S. capitis, S. cohnii and S. warneri isolated from infection sites of animals
Strain/isolate
Year of
isolation Animal Infection
Antibiotic resistance properties and resistance breakpoints (mg/L)
OXA PEN GEN/KAN KAN STR STH ERY CLI TMP TET CHL TIA FUS SMX
CIP
.0.25 .0.125 .1/.16 .16 .16 ND .2 .0.5 .4 .2 .8 NA .1 .256
.1
GyrA GrlA
S. haemolyticus (n¼17)
KM827-07 2007 horse abscess mecA blaZ aac(6′)-Ie – aph(2′)-Ia ant(6)-Ia erm(C), msr,
mph(C)
erm(C),
lnu(A)
dfr(G) tet(K) catpC221 vga(A) R S84L
KM1758-08 2008 cat urinary tract mecA blaZ aac(6′)-Ie – aph(2′)-Ia aph(3′)-III ant(6)-Ia sat4 msr, mph(C) R dfr(G) vga(A) R S84L
KM1632-08 2008 cat urinary tract mecA blaZ aac(6′)-Ie – aph(2′)-Ia aph(3′)-III ant(6)-Ia sat4 msr, mph(C) R S84L
KM785-09 2009 dog abscess mecA blaZ aac(6′)-Ie – aph(2′)-Ia ant(6)-Ia msr, mph(C) dfr(G) tet(K) catpC221 R S84L
KM1183-09 2009 horse dermis mecA blaZ aac(6′)-Ie – aph(2′)-Ia aph(3′)-III ant(6)-Ia erm(C), msr,
mph(C)
erm(C) tet(K) catpC223 DS R S84L
KM1230-09 2009 horse respiratory
tract
mecA blaZ aac(6′)-Ie – aph(2′)-Ia aph(3′)-III ant(6)-Ia sat4 dfr(G) tet(K) R S84L
IMD1272-11 2011 cat urinary tract mecA blaZ aac(6′)-Ie – aph(2′)-Ia str msr lnu(A) tet(K) catpC221 R S84L
IMD1277-11 2011 cat dermis mecA blaZ aac(6′)-Ie – aph(2′)-Ia aph(3′)-III ant(6)-Ia sat4 msr vga(A) R R S84F
IMD1517-11 2011 cat urinary tract mecA blaZ aac(6′)-Ie – aph(2′)-Ia aph(3′)-III ant(6)-Ia sat4 dfr(G) tet(K) R S84F
IMD1519-11 2011 cat dermis mecA blaZ aac(6′)-Ie – aph(2′)-Ia aph(3′)-III sat4 erm(C) erm(C) tet(K) S84L
IMD1521-11 2011 cat dermis mecA blaZ aac(6′)-Ie – aph(2′)-Ia aph(3′)-III ant(6)-Ia sat4 msr dfr(G) R S84L D84Y
IMD1266-11 2011 dog dermis mecA blaZ aac(6′)-Ie – aph(2′)-Ia ant(6)-Ia erm(C) erm(C),
lnu(A)
R S84L
IMD1397-11 2011 dog ear mecA blaZ aac(6′)-Ie – aph(2′)-Ia ant(6)-Ia msr lnu(A) tet(K) R S84F
IMD1532-11 2011 dog dermis mecA blaZ aac(6′)-Ie – aph(2′)-Ia aph(3′)-III sat4 msr dfr(G) tet(K) R S84L
IMD1761-11 2011 dog abscess mecA blaZ aac(6′)-Ie – aph(2′)-Ia aph(3′)-III ant(6)-Ia sat4 erm(C) erm(C) R S84L
IMD1768-11 2011 dog abscess mecA blaZ aac(6′)-Ie – aph(2′)-Ia aph(3′)-III str sat4 erm(C) erm(C) tet(K) catpC223 R S84L
IMD1775-11 2011 dog urinary tract mecA blaZ aac(6′)-Ie – aph(2′)-Ia aph(3′)-III ant(6)-Ia sat4 erm(C), msr erm(C) dfr(G) tet(K) R R S84L
S. hominis (n¼3)
IMD1515-11 2011 dog abscess mecA blaZ aac(6′)-Ie – aph(2′)-Ia aph(3′)-III erm(C) erm(C) tet(K) R S84F G84Y
IMD1516-11 2011 dog joint mecA blaZ aac(6′)-Ie – aph(2′)-Ia erm(C) erm(C) tet(K) R S84F G84Y
IMD1762-11 2011 dog ear mecA blaZ aac(6′)-Ie – aph(2′)-Ia erm(C) erm(C) tet(K) R S84F G84Y
S. capitis (n¼1)
KM1385-1970 2011 dog joint mecA R
S. cohnii (n¼1)
IMD1771-11 2011 dog urinary tract mecA erm(A) erm(A) DS R
S. warneri (n¼1)
IMD1530-11 2011 dog ear mecA blaZ aac(6′)-Ie – aph(2′)-Ia str erm(C) erm(C) catpC221
CHL, chloramphenicol; CIP, ciprofloxacin; CLI, clindamycin; ERY, erythromycin; FUS, fusidic acid; GEN, gentamicin; KAN, kanamycin; OXA, oxacillin; PEN, penicillin; STR, streptomycin; STH,
streptothricin; TET, tetracycline; TIA, tiamulin; TMP, trimethoprim; SMX, sulfamethoxazole; ND, not defined, susceptibility to streptothricin was not measured, only the gene was
detected; NA, no resistance breakpoint available for tiamulin [resistance to tiamulin was attributed in the presence of the vga(A) gene (MIC .4 mg/L)]; DS, decreased susceptibility to
tiamulin with MIC .4 mg/L); R, resistant phenotype, no resistance genes were determined; blank spaces indicate either no resistance or no mutations.
The MIC breakpoints (in mg/L) that determine resistance were those recommended by EUCAST for staphylococci (www.eucast.org). Resistance breakpoints for streptomycin and kana-
mycin were those recommended by the French Society for Microbiology (www.sfm-microbiologie.org) and the resistance breakpoint for sulfamethoxazole was that recommended by
the CLSI.36
Antibiotic resistance genes and their functions are indicated as follows: mecA, methicillin-resistance gene encoding PBP2a for resistance to all b-lactam antibiotics; blaZ, b-lactamase
gene; aac(6′)-Ie–aph(2′)-Ia, aminoglycoside acetyltransferase and phosphotransferase tandem genes; aph(3′)-III, kanamycin phosphotransferase; ant(6)-Ia, streptomycin adenylnucleo-
tidyltransferase gene; str, streptomycin adenyltransferase gene; sat4, strepthotricin acetyltransferase gene; erm(C), macrolide, lincosamide and streptogramin B 23S rRNA methylase gene;
msr, macrolide and streptogramin ATP binding transporter gene; mph(C), macrolide phosphotransferase gene; dfr(A), dfr(G), trimethoprim resistance dihydrofolate reductase gene; lnu(A),
lincosamide nucleotidyltransferase gene; tet(K), tetracycline efflux resistance gene; catpC221, catpC223, chloramphenicol acetyl transferase gene; vga(A), pleuromutilin and streptogramin A
ATP binding transporter gene.
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Table 3. Clinical data, therapy and outcome of treatment of infections associated with MRCoNS in animals (dogs, cats and horses)
Animals (n¼27) and
CoNS Strains Type of infection
History of antibiotic treatment
before identification of the
Staphylococcus (no. of courses)
Resistance profile of
isolated
Staphylococcus from
infection side
Antibiotics used for
treatment of the
Staphylococcus
infection
Incompatibility
with resistance
mechanism Outcome
Dogs (n¼11)
S. haemolyticus KM 785-09 abscess
(granuloma)
amox-clav (1), clindamycin (2) PEN, OXA, KAN, GEN,
STR, ERY, TET,
TMP, CHL
clindamycin no recovery
S. capitis KM1385-1970 joint (surgery) amox-clav (1), clindamycin (2) PEN, OXA amox-clav,
clindamycin
no unknown
S. epidermidis KM1385-1972
S. haemolyticus IMD1266-11 eye (chronic
conjunctivitis)
cefovecin (1), neomycin/polymyxin
B (2)
PEN, OXA, STR, ERY,
CLI, CIP
tetracycline no relapse if
treatment
with
tetracycline
stops
S. epidermidis IMD1765-11 respiratory tract
(chronic
cough)
amox-clav (1), amox-clav (2),
amox-clav (3),
PEN, OXA, KAN, GEN,
STR, ERY, TMP, CLI,
CHL
marbofloxacin,
tetracycline
no recovery after a
4 week
therapy
S. hominis IMD1762-11 ear (otitis
externa)
no antibiotics PEN, OXA, KAN, GEN,
ERY, CLI, TET, CIP
framycetin yes [aac(6′)-Ie –
aph(2′)-Ia]
recovery
S. warneri IMD1530-11 ear (chronic
otitis externa,
relapse)
polymyxin B (1), marbofloxacin (2),
cefalexin (3), marbofloxacin (4)
PEN, OXA, KAN, GEN,
STR, ERY, CLI, CHL
marbofloxacin no relapse
S. epidermidis IMD1766-11 ear (chronic
otitis externa)
metronidazole (1), fusidic acid/
framycetin (2), polymyxin B (3),
amox-clav (4), enrofloxacin (5)
PEN, OXA, ERY, CLI,
CIP
amox-clav yes (mecA) recovery
S. haemolyticus IMD1775-11 urinary tract
(preputial
catarrh)
amox-clav (1), polymyxin B (2) PEN, OXA, KAN, GEN,
STR, ERY, TMP, CLI,
TET, CIP
amox-clav yes (mecA) recovery
S. haemolyticus IMD1768-11 abscess amox-clav/tetracycline (1),
amox-clav (2), amox-clav (3),
tetracycline (4), amox-clav (5)
PEN, OXA, KAN, GEN,
STR, ERY, TMP, CLI,
CHL, TET, CIP
cefalexin yes (mecA) relapse
S. haemolyticus IMD1761-11 abscess amox-clav (1), amox-clav/
chloramphenicol (2), amox-clav/
chloramphenicol (3),
aminoglycoside/polymyxin B (4)
PEN, OXA, KAN, GEN,
STR, ERY, CLI, CIP
chloramphenicol no recovery
S. hominis IMD1515-11 dermis (ulcer) amox-clav (1), cefalexin (2) PEN, OXA, KAN, GEN,
STR, ERY, CLI, TET,
CIP
no treatment NA euthanasia
Cats (n¼11)
S. haemolyticus KM1758-08 urinary tract marbofloxacin (1), amox-clav (2),
rifampicin (3)
PEN, OXA, KAN, GEN,
STR, ERY, TMP, CIP,
TIA
rifampicin no recovery
S. haemolyticus KM1632-08 urinary tract amox-clav (1), trimethoprim/
sulphonamide (2)
PEN, OXA, KAN, GEN,
STR, ERY
trimethoprim/
sulphonamide
no recovery
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S. epidermidis KM1527-07 abscess after
surgery
marbofloxacin (1), amox-clav (2) PEN, OXA, KAN, GEN,
STR, ERY, TMP,
TET, TIA
marbofloxacin,
tetracycline
yes [tet(K)] recovery after
amputation of
the lower
extremity
S. epidermidis KM505-09 urinary tract enrofloxacin (1), amoxicillin (2),
marbofloxacin (3)
PEN, OXA, KAN, GEN,
TMP, CLI, TET,
CHL, CIP
no treatment NA recovery
S. haemolyticus IMD1272-11 urinary tract
(urolithiasis,
chronic
cystitis)
amox-clav (1) PEN, OXA, KAN, GEN,
STR, ERY, CLI, TET,
CHL, CIP
clindamycin yes [erm(C)] recovery
S. haemolyticus IMD1517-11 urinary tract unknown PEN, OXA, KAN, GEN,
STR, TMP, TET, CIP
no treatment (fast
death)
NA death
S. epidermidis IMD1776-11 eye (corneal
ulcer)
enrofloxacin (1), moxifloxacin (2),
gentamicin (3)
PEN, OXA, KAN, GEN,
STR, ERY, TMP, CLI,
CHL, CIP
ofloxacin,
tetracycline
no recovery
(together with
cross-linking
therapy)
S. epidermidis IMD1763-11 urinary tract
(urolithiasis,
chronic
cystitis)
cefovecin (1) PEN, OXA, KAN, GEN,
TET
marbofloxacin no relapse (cystitis
with
Enterococcus)
S. epidermidis IMD1270-11 phlegmone
(acneic skin)
cefovecin (1) PEN, OXA, KAN, GEN,
STR, ERY, TMP,
TET, TIA; CIP
chloramphenicol no recovery
S. epidermidis IMD1269-11 urinary tract
(cystitis)
marbofloxacin (1), amox-clav (2) PEN, OXA, KAN, GEN,
ERY, CLI, CIP
amox-clav yes (mecA) recovery
S. epidermidis IMD1274-11 eye
(conjunctivitis)
amox-clav (1), enrofloxacin/
amoxicillin (2), amoxicillin (3),
amoxicillin (4), amoxicillin (5),
amoxicillin (6), bacitracin/
neomycin/ofloxacin (7),
amoxicillin (8), ciprofloxacin (9),
amoxicillin (10), cefovecin (11),
ciprofloxacin/amoxicillin(12),
amoxicillin (13), amoxicillin (14)
PEN, OXA, ERY, CLI,
TET, CIP
neomycin/polymyxin
B
no relapse
Horses (n¼5)
S. epidermidis KM794-06 abscess penicillin PEN, OXA, KAN, GEN,
TET
unknown NA recovery
S. epidermidis KM825-09 abscess (surgery) cefquinome (1), penicillin/
gentamicin (2)
PEN, OXA, KAN, GEN no treatment NA euthanasia
S. haemolyticus KM827-07 wound penicillin/gentamicin (1),
enrofloxacin (2), cefquinome (3)
PEN, OXA, KAN, GEN,
STR, ERY, TMP, CLI,
TET, CHL, TIA
unknown NA recovery
S. haemolyticus KM1183-09 dermis trimethoprim/sulphonamide (1),
cefquinome (2), marbofloxacin/
enrofloxacin (3)
PEN, OXA, KAN, GEN,
STR, ERY, CLI, TET,
CHL
gentamicin yes [aac(6′)-Ie –
aph(2′)-Ia]
relapse
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Results
Identification of and genetic diversity among strains of
MRCoNS
The 43 samples originated from animals admitted to 30 different
clinics from 10 different cantons in Switzerland, indicating that
MRCoNS are widespread and not related to a specific clinic with
nosocomial infection problems (Figure 1). MRCoNS were isolated
from different infection sites in cats (n¼16), dogs (n¼20) and
horses (n¼7) (Tables 1 and 2). Infected sites consisted of the
skin (n¼10), urinary tracts (n¼9), ears (n¼4), respiratory
tracts (n¼5), joints (n¼4), eyes (n¼1) and abscesses/fistulas
(n¼10) (Tables 1 and 2). The MRCoNS were identified as S. epider-
midis (Table 1) and S. haemolyticus, S. hominis, S. warneri,
S. capitis and S. cohnii (Table 2). Three samples contained an
additional pathogen, i.e. Staphylococcus schleiferi together with
S. haemolyticus KM785-09, Staphylococcus pseudintermedius to-
gether with S. epidermidis KM1077-09 and a mix of anaerobic
bacteria together with S. epidermidis IMD1522-11.
PFGE revealed a large heterogeneity between the MRCoNS of
the same species. Eight different PFGE clonal lineages were identi-
fied among the 17 S. haemolyticus isolates, 11 among the 20
S. epidermidis isolates and 1 among the 3 S. hominis isolates
(Figure 1). The S. epidermidis strains showed distinct MLSTpatterns
andbelonged to14different sequence types (STs), representing 11
clonal complexes (CC), namely CC2 [ST2 (n¼4), ST446 (n¼1)], CC5
[ST5 (n¼3), ST445 (n¼1)], CC22 [ST22 (n¼3)], CC59 [ST59 (n¼1),
ST81 (n¼1)], CC17 [ST69 (n¼1), CC89 [ST89 (n¼1)], CC130 [ST450
(n¼1)], CC166 [ST449 (n¼1)], CC286 [ST286 (n¼1)], CC451
[ST451 (n¼1)] and CC448 [ST448 (n¼1)]. ST445, ST446, ST448,
ST449, ST450 and ST451 were newly described STs [Figure 1 and
Figure S1 (available as Supplementary data at JAC Online)]. All
but one of the isolates belonging to the predominant CC2 (n¼5),
CC5 (n¼4), CC22 (n¼2) and CC59 (n¼2) clustered into four dis-
tinct PFGE branches (Figure 1). However, different PFGE patterns
could still be observed within these groups, indicating a larger di-
versity between strains of the same CC (Figure 1).
Ten of 20 S. epidermidis isolates harboured the biofilm forma-
tion operon ica, including all the CC2 (ST2, ST446) (n¼5) and
ST22 (n¼2) isolates aswell as the ST69, ST448 and ST449 isolates.
The icaA gene was also detected in one S. hominis isolate. ACMEs
were only detected in S. epidermidis. Eight S. epidermidis isolates
carried a type I ACME (arcA+ /opp3AB+) and three carried a
type II ACME (arcA+ /opp3AB2). ACMEs were found in all ST5
and ST22 isolates, but were also present in one ST2 isolate and
in the ST59, ST69, ST446, ST449 and ST450 isolates (Figure 1). An
SCCmec element could only be typed for 17 isolates. SCCmec IV
was detected in one S. capitis, one S. warneri and eight S. epidermi-
dis isolates. In S. epidermidis, SCCmec IVwasassociatedwithACME
type I in the ST5, ST69 and ST450 isolates and with ACME type 2 in
the ST59 isolate. SCCmec Vwas detected in seven S. haemolyticus
isolates (Figure 1). The other 26 SCCmec elements could not be
characterized as they lacked either known ccr genes or a known
mecA class structure or both (Figure 1).
Distribution of MRCoNS isolates in veterinary practices
Association of a specific clonal lineage with a clinic was only
observed for two pairs of S. haemolyticus (IMD1761-11, IMD1768-
11 and IMD1632-08, IMD1758-08) isolated from differentTa
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animals in two clinics. Each pair showed similar PFGE profiles (A and
C) and contained a non-typeable SCCmec element (Figure 1).
However, they exhibited different antibiotic resistance profiles
(Table 2). Otherwise, MRCoNS isolated from animals admitted to
the same clinic were genetically distant. On the other hand, genet-
ically related MRCoNSwere isolated from different animals in differ-
ent clinics (Figure 1). These isolates also displayed different
antibiotic resistance profiles (Tables 1 and 2).
Antibiotic resistance profile
All the MRCoNS isolates were resistant to b-lactam antibiotics
and contained the mecA gene. None of them was resistant to
linezolid, quinupristin/dalfopristin, rifampicin or vancomycin.
Nonetheless, the isolates were also resistant to gentamicin/
kanamycin owing to the bifunctional acetyltransferase/phospho-
transferase gene aac(6′)-Ie–aph(2′)-Ia (n¼33), kanamycin
[aph(3′)-III (n¼17)], macrolides and/or lincosamides [erm(C)
(n¼22), erm(A) (n¼1), msr (n¼12) and lnu(A) (n¼4], tetracyc-
line [tet(K) (n¼22)], trimethoprim [dfr(A) (n¼7) and dfr(G)
(n¼10)], streptomycin [str (n¼5) and ant(6)-Ia (n¼15)], strepto-
thricin [sat4 (n¼15)], chloramphenicol [catpC221 (n¼5) and
catpC223 (n¼3)], tiamulin [(vga(A) (n¼4)], mupirocin [mupR
(n¼2)], fusidic acid (n¼13), sulfamethoxazole (n¼34) and fluor-
oquinolones (n¼30) (Tables 1 and 2). Resistance mechanisms
Strain Species ST animal clinic group SCCmec ACME biofilm
IMD1530-11 S. warneri dog ZH8 R IV negative
IMD1771-11 S. cohnii dog BL1 S NT negative
IMD1528-11 S. epidermidis ST448 cat BL4 CC448 NT negative icaA
IMD1776-11 S. epidermidis ST286 cat ZH7 CC286 NT negative
IMD1764-11 S. epidermidis ST449 dog TI1 CC166 NT(C4B) type II icaA
KM1077-09 S. epidermidis ST2 dog VD3 CC2 NT(4A) type I icaA
KM825-09 S. epidermidis ST451 horse BL2 CC451 IV negative
IMD1265-11 S. epidermidis ST69 horse BL2 CC17 IV type I icaA
KM794-06 S. epidermidis ST89 horse BE2 CC89 NT negative
IMD1778-11 S. epidermidis ST5 dog BL1 CC5 IV type I
IMD1274-11 S. epidermidis ST5 cat ZH1 CC5 IV type I
IMD1766-11 S. epidermidis ST5 dog ZH5 CC5 IV type I
IMD1269-11 S. epidermidis ST445 cat ZH6 CC5 NT negative
KM1527-07 S. epidermidis ST22 cat VD2 CC22 NT(4A) type II icaA
KM505-09 S. epidermidis ST22 cat GE1 CC22 NT(4A) type I icaA
IMD1270-11 S. epidermidis ST2 cat ZH4 CC2 NT(4B) negative icaA
IMD1765-11 S. epidermidis ST2 dog ZH3 CC2 NT negative icaA
KM92-09 S. epidermidis ST2 dog VD1 CC2 NT(CA) negative icaA
CSNO38 S. epidermidis ST446 horse BE2 CC2 NT type I icaA
IMD1763-11 S. epidermidis ST81 cat BL3 CC59 IV negative
KM827-09 S. epidermidis ST59 cat GR1 CC59 IV type II
KM1385-1972 S. epidermidis ST450 dog BE1 CC130 IV type I
IMD1532-11 S. haemolyticus dog TI1 L V negative
IMD1521-11 S. haemolyticus cat VD5 M NT negative
KM1632-08 S. haemolyticus cat BE1 C NT negative
KM1758-08 S. haemolyticus cat BE1 C NT negative
KM1183-09 S. haemolyticus horse BE2 D V negative
IMD1519-11 S. haemolyticus cat AG1 E V negative
IMD1266-11 S. haemolyticus dog BE4 H NT(CA) negative
IMD1397-11 S. haemolyticus dog U1 I NT negative
IMD1775-11 S. haemolyticus dog SH1 F V negative
KM1230-09 S. haemolyticus horse BE2 G V negative
IMD1517-11 S. haemolyticus cat SH2 J V negative
IMD1761-11 S. haemolyticus dog ZH1 A NT negative
IMD1768-11 S. haemolyticus dog ZH1 A NT negative
IMD1272-11 S. haemolyticus cat AG2 K NT negative
IMD1277-11 S. haemolyticus cat GE2 N V negative
KM785-09 S. haemolyticus dog BE1 O NT negative
KM827-07 S. haemolyticus horse BE2 P NT negative
KM1385-1970 S. capitis dog BE1 Q IV negative
IMD1515-11 S. hominis dog AI1 T NT negative
IMD1516-11 S. hominis dog ZH9 T NT negative icaA
IMD1762-11 S. hominis dog ZH2 T NT negative
10
0
90807060504030
Figure 1. Phylogenetic tree constructed from the PFGE pattern of methicillin-resistant S. epidermidis, S. haemolyticus, S. hominis, S. capitis and
S. warneri. The tree was generated by UPGMA using Bionumerics 6.6 (Applied Maths, Kortrjk, Belgium) and comparison settings (Dice, optimization
1.5%, position tolerance 1.5%) as recommended by PulseNet International (www.pulsenetinternational.org). The broken line indicates the cut-off
value of ≥79%, determining clonality between the isolates according to Miragaia et al.47 Capital letters indicate the cantons and the numbers
indicate the different clinics. AG, Argovia; AI, Appenzell Inner Rhoden; BE, Bern; BL, Basel-Land; GE, Geneva; GR, Grisons; SH, Schaffhausen; TI,
Ticino; VD, Vaud; ZH, Zurich; U, unknown.
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for fusidic acid and sulfamethoxazole were not investigated.
Fluoroquinolone resistance was attributed to mutations in topo-
isomerase II GyrA (n¼30) and topoisomerase IV GrlA (n¼18)
(Tables 1 and 2). Mutations that cause amino acid substitutions
in topoisomerases II and IV were found in ciprofloxacin-resistant
S. epidermidis, S. haemolyticus and S. hominis at nucleotide pos-
ition 251 [n¼30; Ser84Leu (n¼14), Ser84Phe (n¼13), Ser84Tyr
(n¼3)] in gyrA and at positions 239 [n¼8; Ser80Tyr (n¼4),
Ser80Phe (n¼4)] and 250 [n¼10; Asp84Tyr (n¼7), Gly84Tyr
(n¼3)] in grlA. An amino acid substitution in GrlB (Glu473Lys)
was also present in two S. epidermidis isolates (KM505-09 and
KM1527-07) and two S. haemolyticus isolates (IMD1277-11
and IMD1532-11). This mutation was not considered as being re-
sponsible for fluoroquinolone resistance in CoNS, as a mutation
at the same location has been shown not to confer resistance
to fluoroquinolones in Staphylococcus aureus.38 The resistance
mechanism could not be explained for one strain with resistance
to gentamicin and kanamycin, for one strain with resistance to
clindamycin and for two strains with decreased susceptibility to
tiamulin (MIC .4 mg/L), suggesting new mechanisms of
resistance.
Clinical data of infected animals
Clinical data were obtained for 27 animals (11 dogs, 11 cats and
5 horses) admitted to 19 different clinics (Table 3). Twenty-four
animals had a history of antibiotic treatment, and 20 of them
underwent antimicrobial treatment more than twice with up to
14 courses. The most commonly used antibiotics in dogs and
cats prior to the identification of the staphylococcal species
were amoxicillin/clavulanic acid, cephalosporins and fluoroquino-
lones. In 20 dogs and cats treated, amoxicillin was given 15
times, fluoroquinolones 8 times, cephalosporins 6 times, and
both a b-lactam and a fluoroquinolone antibiotic were given 7
times. Antibiotics such as gentamicin, chloramphenicol, tetracyc-
line and clindamycin were also used in pets, but less frequently.
In horses, cefquinome, fluoroquinolones and the combination
penicillin/gentamicin were the most commonly administered
antibiotics. The MRCoNS infections were then treated after con-
sultation of an antibiogram, most frequently using fluoroquino-
lones or amoxicillin/clavulanic acid followed by tetracycline,
clindamycin, chloramphenicol, cefalexin, the combination sul-
phonamides/trimethoprim, rifampicin and the aminoglycosides
gentamicin, framycetin and neomycin. Most of the animals
(n¼14) recovered after antibiotic treatment: six had a relapse,
two recovered without any antibiotic therapy, one recovered
after amputation of the infected lower extremity, one was still
under treatment at the time of writing, two were not further
treated and euthanized and one died of unknown cause prior
to therapy. In seven cases, antibiotics were used even in the
presence of resistance, leading to relapse in two cases when
cefalexin and gentamicin were used for the treatment of an
abscess and skin infection, respectively. The other five animals
recovered after antimicrobial treatment with amoxicillin/clavula-
nic acid (n¼3), clindamycin (n¼1) or framycetin (n¼1), despite
the presence of mecA, erm(C) or aac(6′)-Ie–aph(2′)-Ia in the re-
spective MRCoNS (Table 3). For these animals, MRCoNS were likely
not the primary cause of the infection (three urinary tract and
two ear infections), although MRCoNS appeared alone in the
culture. No significant difference was observed in the outcome
of the disease between animals treated with an antibiotic incom-
patible and an antibiotic compatible with the resistance profile of
the MRCoNS.
Discussion
MRCoNS are associated with serious infections in animals and
have become a challenge to therapy. The CoNS species identified
in this study were the same as the ones causing nosocomial
infections in humans, with S. epidermidis and S. haemolyticus
being the most prevalent in animals and humans.7 Similar to
the case with human infections,11,13 S. hominis, S. warneri,
S. cohnii and S. capitis were only occasionally isolated from
animal infection sites. The population analysis by PFGE showed
that the majority of the isolates are genetically diverse. Three
clonal lineages sharing similar PFGE profiles appeared to be pre-
dominant among S. epidermidis and were found to belong to
CC2, CC5 and CC22. However, isolates of CC2 and CC22 contained
divergent SCCmec elements and ACMEs, while CC5 isolates
almost exclusively contained SCCmec IV and ACME type I. Add-
itionally, these clonally related isolates displayed different resist-
ance profiles, emphasizing the ability of CoNS to acquire
antibiotic resistance genes. The presence of numerous PFGE and
antibiotic resistance profiles is a well-described phenomenon for
S. epidermidis ST2, which is the most widely disseminated
human healthcare-associated sequence type worldwide.39–42
A study using 217 S. epidermidis isolates from humans from
17 countries detected 30.9% of the isolates as ST2.42 The suc-
cessful spread of ST2 in the hospital environment has been sug-
gested to be associated with its ability to generate novel
phenotypic and genotypic variants by recombination and acqui-
sition of new elements, such as the biofilm-formation ica operon,
ACMEs and antibiotic resistance genes.14,15,18,41 In our study, all
isolates of CC2 and CC22, which is a subcluster of CC2 (Figure S1,
available as Supplementary data at JAC Online), contained the
biofilm formation operon ica. On the other hand, the ica
operon was absent in isolates of CC5, which was also predomin-
ant in infection sites of animals; they contained ACMEs instead.
Of note, CC22 contained both ica and ACMEs. The presence of
the biofilm formation operon ica and ACMEs almost exclusively
in S. epidermidis of the predominant clonal lineages CC2, CC5
and CC22 may have contributed to the establishment of these
strains in the animal environment. In addition to the predomin-
ant STs, the animals were also infected with other S. epidermidis
strains, which has also been reported in human infections, such
as ST35, ST59, ST81, ST69, ST89 and ST286 (Figure S1, available
as Supplementary data at JAC Online),40–42 and with S. haemo-
lyticus. The absence of MLST methods for S. haemolyticus pre-
vented us from determining whether specific STs would also be
predominant within this species. However, the different PFGE
and antibiotic resistance profiles support the hypothesis that
MRCoNS associated with infections in animals are very heteroge-
neous, unlike methicillin-resistant S. pseudintermedius (MRSP),
which spread as specific clones.43 Nevertheless, MRSP and
MRCoNS are resistant to the same classes of drugs and contain
similar antibiotic resistance genes. Similar to MRSP, more than
two-thirds of the MRCoNS exhibit resistance to fluoroquinolones,
macrolides, lincosamides and aminoglycosides, in addition to
resistance to b-lactams, suggesting that they have been selected
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through the frequent use of antibiotics. These classes of drugs,
especially the b-lactams and fluoroquinolones, were also the
most commonly used drugs in veterinary practices (Table 3).
These two classes of drugs have been shown to represent a sig-
nificant risk factor for the selection of methicillin-resistant S.
aureus44 and similar effects are to be expected for MRCoNS.
Many animals were given more than one antibiotic course,
with some animals receiving 5 and up to 14 courses of an anti-
biotic before the MRCoNS infection was diagnosed. The series of
empirical antimicrobial treatments may have contributed to the
selection of the MRCoNS in the infection sites. Additionally, the
primary cause of the infection may have been overlooked and
not directly related to the presence of a MRCoNS. Indeed, two
animals recovered without antibiotic treatment and five recov-
ered despite the presence of a resistance mechanism against
the antibiotic used for treatment. Nevertheless, in the majority
of the cases the staphylococcal infections could be treated
with an antibiotic chosen after consultation of an antibiogram.
All these criteria highlight the importance of correct diagnosis
and antibiograms.
Multidrug-resistant CoNS represent a new challenge for
therapy in veterinary medicine. The infections are caused by gen-
etically distant strains, indicating many possible non-hospital-
related reservoirs, such as animals themselves, animal owners
and people working with animals that have been shown to
harbour and possibly exchange MRCoNS.22,45,46 The presence of
clones similar to those causing infections in humans highlights
the importance of careful surveillance of bacterial infection dis-
eases, the need to implement infection control programmes
and the prudent use of antibiotics in veterinary settings.
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